Channel Therapeutics Corp financial data

Symbol
CHRO on NYSE
Location
685 Us Highway One, North Brunswick, NJ
State of incorporation
NV
Fiscal year end
December 31
Former names
Chromocell Therapeutics Corp (to 11/15/2024)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 76.1 %
Debt-to-equity -418 %
Return On Equity 996 % +632%
Return On Assets -314 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.1M shares +3.85%
Common Stock, Shares, Outstanding 6.1M shares +56.3%
Entity Public Float 6.8M USD
Common Stock, Value, Issued 613 USD +56.8%
Weighted Average Number of Shares Outstanding, Basic 5.57M shares +337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.18M USD -54.3%
General and Administrative Expense 4.11M USD +50.1%
Operating Income (Loss) -7.57M USD -10.3%
Nonoperating Income (Expense) -383K USD +26.1%
Net Income (Loss) Attributable to Parent -7.96M USD -7.78%
Earnings Per Share, Basic -1.43 USD/shares +75.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.8M USD
Assets, Current 1.37M USD +1320%
Assets 1.37M USD +1320%
Accrued Liabilities, Current 308K USD
Liabilities, Current 4.08M USD -37.6%
Liabilities 4.08M USD -37.6%
Retained Earnings (Accumulated Deficit) -21.5M USD -58.8%
Stockholders' Equity Attributable to Parent -2.71M USD +57.9%
Liabilities and Equity 1.37M USD +1320%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.99M USD -1049%
Net Cash Provided by (Used in) Financing Activities 5.67M USD +3295%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 6.1M shares +56.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 513K USD +433%
Deferred Tax Assets, Valuation Allowance 5.59M USD +54.2%
Deferred Tax Assets, Gross 5.59M USD +54.2%
Additional Paid in Capital 18.8M USD +165%